Thomas Seufferlein
YOU?
Author Swipe
View article: Crew resource management and threat and error management improve team communication in endoscopy: a prospective study
Crew resource management and threat and error management improve team communication in endoscopy: a prospective study Open
In gastrointestinal endoscopy, the ability to perform increasingly complex procedures has significantly heightened the demand for effective team cooperation. Crew Resource Management (CRM) and Threat and Error Management (TEM), proven stra…
View article: Peptide-based inhibition of CD44v6 renders liver carcinomas more susceptible to therapeutic intervention
Peptide-based inhibition of CD44v6 renders liver carcinomas more susceptible to therapeutic intervention Open
Cluster of differentiation 44 variant 6 (CD44v6) has been described in various types of cancer, including liver cancer. Despite significant advancements in cancer therapy, there is still an urgent medical need for new therapeutic strategie…
View article: DKK3 Initially Preserves Acinar Integrity Through MEK‐Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer
DKK3 Initially Preserves Acinar Integrity Through MEK‐Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is characterized by its intricate biology governed by spatiotemporal dynamics in the expression and function of specific proteins. Here, DKK3 is identified as a dynamic player with a dual role in PDA…
View article: Indian Consensus Guidelines for the Management of Pancreatic Cancer
Indian Consensus Guidelines for the Management of Pancreatic Cancer Open
Pancreatic cancer needs a multidisciplinary approach to treatment. These consensus statements encompass all aspects of treatment of pancreatic cancer within the Indian context. This article outlines consensus-based Indian guidelines for pa…
View article: Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer
Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a devastating prognosis. Gemcitabine, a pyrimidine anti-metabolite, is a cornerstone in PDAC therapy. However, resistance remains a major hurdle in clinical care. Resistan…
View article: Integrated, Cross-Entity Information on Preventive Measures for Bowel, Breast, and Prostate Cancer: Evaluation Study of the Web Application “Prevent-Take-Up”
Integrated, Cross-Entity Information on Preventive Measures for Bowel, Breast, and Prostate Cancer: Evaluation Study of the Web Application “Prevent-Take-Up” Open
Background About 40% of cancers are preventable through evidence-based interventions; however, uptake remains suboptimal. Knowledge and acceptance of primary and secondary preventive measures in the general population is not sufficient. We…
View article: Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy
Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy Open
Background Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a high mortality rate. While up to 20% of PDAC patients harbor mutations in genes involved in homologous recombination (HR) repair, only 5% of germline BRC…
View article: Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy
Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy Open
Patient-derived xenografts (PDX) and organoids (PDO) are widely used to model cancer and predict treatment response in matched patients. However, their predictive accuracy has not been systematically studied nor compared. We conducted a sy…
View article: Prevalence of Fluid Overload in a Cohort of Patients with Acute Pancreatitis: Results from a Retrospective Tertiary Single-center Study
Prevalence of Fluid Overload in a Cohort of Patients with Acute Pancreatitis: Results from a Retrospective Tertiary Single-center Study Open
Objectives: Aggressive fluid expansion has been an undisputed aspect about navigating the early stages of acute pancreatitis. Evidence produced by the WATERFALL trial supports a more conservative approach to fluid resuscitation as patients…
View article: Impact of preoperative radiotherapy on patient‐reported outcomes in rectal cancer
Impact of preoperative radiotherapy on patient‐reported outcomes in rectal cancer Open
Aim To prospectively evaluate the effect of preoperative radiotherapy followed by surgery versus surgery alone on patient‐reported outcomes (PROs) 1 year after surgery. Method Prospective observational cohort study in 127 colorectal cancer…
View article: Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study Open
PURPOSE Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previously demonstrated in patients with advanced pancreatic…
View article: Self-reported financial difficulties of colorectal cancer patients 1 year after start of treatment
Self-reported financial difficulties of colorectal cancer patients 1 year after start of treatment Open
A significant proportion of CRC patients report FDs 1 year after treatment initiation, particularly among socioeconomically disadvantaged groups. Together with the predictive models and two ready-to-use risk assessment tables, these findin…
View article: Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution
Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution Open
SUMMARY Patient-derived organoids (PDOs) reflect parental tumor features and may represent promising avatars for prognosticating drug response. Here, we recruited 169 patients with pancreatic cancer (PC) and established a living biobank in…
View article: Novel peptide targeting CXCR4 disrupt tumor-stroma crosstalk to eliminate migrating cancer stem cells
Novel peptide targeting CXCR4 disrupt tumor-stroma crosstalk to eliminate migrating cancer stem cells Open
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and metastatic malignancies worldwide. Migrating cancer stem cells (miCSCs) marked by CD133+CXCR4+ expression drives metastasis but lacks effective drug targets. Here, w…
View article: Unveiling the intriguing relationship: oncogenic <scp><i>KRAS</i></scp>, morphological shifts, and mutational complexity in pancreatic mucinous cystic neoplasms
Unveiling the intriguing relationship: oncogenic <span><i>KRAS</i></span>, morphological shifts, and mutational complexity in pancreatic mucinous cystic neoplasms Open
Pancreatic ductal adenocarcinoma (PDAC) often arises from preexisting cystic lesions such as intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN). This study investigated the molecular heterogeneity and mutat…
View article: P1341 Probing the interaction of probiotic bacterial extracellular vesicles with primary colonic epithelium using an ex-vivo organoid platform
P1341 Probing the interaction of probiotic bacterial extracellular vesicles with primary colonic epithelium using an ex-vivo organoid platform Open
Background Bacterial extracellular vesicles (BEV) are increasingly recognized as a relevant mode of contactless host-microbiota communication. BEV are nanoparticles pinched off from the membrane of multiple bacteria and carry nucleic acid …
View article: Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines Open
Background Pancreatic ductal adenocarcinoma (PDAC) is mostly refractory to immunotherapy due to immunosuppression in the tumor microenvironment and cancer cell-intrinsic T cell tolerance mechanisms. PDAC is described as a “cold” tumor type…
View article: Organoid‐based precision medicine in pancreatic cancer
Organoid‐based precision medicine in pancreatic cancer Open
Pancreatic ductal adenocarcinoma (PDAC) ranks among the leading causes of cancer‐related deaths worldwide. Despite advances in precision oncology in other malignancies, treatment of PDAC still largely relies on conventional chemotherapy. G…
View article: Prognostic value of the CRM-status in pancreatic ductal adenocarcinoma - data from a regional cancer registry
Prognostic value of the CRM-status in pancreatic ductal adenocarcinoma - data from a regional cancer registry Open
Background Ductal pancreatic adenocarcinoma (PDAC) still has a dismal prognosis even when deemed resectable. A cancer free resection margin (R0) is associated with a more favourable prognosis than the presence of tumour cells at resection …
View article: An Adaptable Protocol to Generate a Murine Enteroid–Macrophage Co-Culture System
An Adaptable Protocol to Generate a Murine Enteroid–Macrophage Co-Culture System Open
Impairment of the intestinal epithelial barrier is frequently seen as collateral damage in various local and systemic inflammatory conditions. The inflammatory process is characterized by reciprocal interactions between the host intestinal…
View article: Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial
Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial Open
Background Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (mAbs) are widely used for tumor treatment, including metastatic colorectal cancer (mCRC). So far, there are no biomarkers that reliably predict resistance to …
View article: Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315)
Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315) Open
PURPOSE First-line therapy options in advanced cholangiocarcinoma (CCA) are based on the ABC-02 trial regimen (gemcitabine/cisplatin [G/C]). The NIFE trial examined nanoliposomal irinotecan/fluorouracil/leucovorin (nal-IRI/FU/LV) as altern…
View article: Efficiency and safety of nasal positive airway pressure systems during endoscopic procedures in high-risk patients: Endo-Breath study
Efficiency and safety of nasal positive airway pressure systems during endoscopic procedures in high-risk patients: Endo-Breath study Open
Background and study aims Sedation of high-risk patients is a relevant issue in interventional endoscopy. This is especially because standard oximetric monitors display only hypoxia and not the preceding hypercapnia. Therefore, the questio…